ClinicalTrials.gg
CompletedNCT06799845SPARK2Updated Oct 19, 2026Results posted

Phase 2B Study Assessing Pain Relief After Replacement of the Knee

A Phase 2 interventional study of ATX101 and bupivacaine hydrochloride in Total Knee Arthroplasty (Postoperative Pain), sponsored by Allay Therapeutics, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Allay Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.

Enrollment
141st of 1,098
226 · median 76
Started
2025
with 48 others
Phase 2
121 of 1,180
9 open now
Registered
1,074th of 1,180
by date

Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 141st largest by enrollment of the 1,098 interventional ones that give a count, is one of 49 that started in 2025, is one of 121 in phase 2, and was the 1,074th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

198 more — sign in →

All 203 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,180 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

The goal of the ATX101-TKA-004 clinical trial aims to evaluate the efficacy and safety of ATX101 1,500 mg in participants undergoing primary unilateral total knee arthroplasty. The study will compare the effectiveness of ATX101 with a saline placebo and bupivacaine, an active comparator. Additionally, it will assess opioid consumption among participants receiving ATX101 versus those given the saline placebo and bupivacaine. The trial will also focus on the safety and tolerability of ATX101 in the participants.

03

Conditions studied

  • Total Knee Arthroplasty (Postoperative Pain)

Browse trials for

Keywords

  • postoperative pain
  • post-surgical pain total knee arthroplasty
  • bupivacaine
  • bupivacaine implant
  • total knee replacement
  • ATX101
  • TKA
  • post-operative pain
  • postsurgical pain
  • post-surgical pain
  • postsurgical pain total knee arthroplasty
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Primary indication of TKA is knee pain due to osteoarthritis or post-traumatic arthritis
  • Scheduled to undergo primary unilateral TKA with a cemented prosthesis, without use of a surgical drain, and under bupivacaine spinal anesthesia (dextrose is permitted)
  • American Society of Anesthesiology (ASA) Physical Classification System of class 1, 2, or 3
  • Capable, able, and willing to comply with all trial visits and procedures. Participant must also be able to use trial required e-diary and demonstrate completion compliance during the screening period
  • English or Spanish speaking, willing, and capable of providing written

Key Exclusion Criteria:

  • Has a planned concurrent surgical procedure (e.g. bilateral TKA) at the time of surgery or a planned surgical procedure before the last trial visit
  • Has had any previous open surgery, (e.g., ORIF for fracture, osteotomy, arthroplasty, unicompartmental knee arthroplasty, or TKA), in the trial knee at any time in the past or arthroscopic surgery within 12 months. Has had any previous surgery in the contralateral knee within 6 months prior to screening
  • Has been administered any type of intra-articular injection within 3 months of surgery in the trial knee
  • Unable to abstain from opioid use for knee pain (including codeine) within 2 weeks (14 days) of surgery
  • Has a (BMI) ≥45 kg/m²
  • Is unwilling or unable to discontinue use of medications or products that can impact pain control from the Screening Visit until the last trial visit (e.g. cannabidiol (CBD) oil, Kratom)
  • Has a medical condition or receiving medication such that, in the opinion of the Investigator, participating in the trial would pose a health risk to the participant or confound the postsurgical assessments or might confound or interfere with the outcome of the trial
  • Has received/used an drug, product, or device for a clinical trial within 30 days of screening. COVID-19 vaccines (approved or under emergency use authorization locally) are permitted if the participant is not in a clinical trial for the vaccine
  • Has a positive drug screen at the Screening Visit or on the day of surgery
  • Has participated in an ATX101 clinical trial
  • Pregnant, breastfeeding, or planning to become pregnant during the trial or before the last trial visit

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    ATX101

    Drug: ATX101

  • Placebo comparator
    saline placebo

    Drug: saline placebo

  • Active comparator
    bupivacaine hydrochloride

    Drug: bupivacaine hydrochloride

Interventions

  • DrugATX101

    ATX101 bupivacaine implants, total of 1,500 mg into the surgical site

  • bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration

  • Drugsaline placebo

    normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to Placebo

    Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

    Time frame: from 30 minutes through 168 hours (Day 8)

Secondary outcomes

  1. AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo

    Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

    Time frame: From 30 minutes through 336 hours (Day 15)

  2. AUC for the NRS-R of Pain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to Placebo

    Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

    Time frame: From 30 minutes through 504 hours (Day 22)

  3. Total Post-surgical Consumption of Opioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo

    Total post-surgical consumption of rescue opioid medications in morphine milligrams equivalent (MME) dose from 30 minutes through 336 hours (Day 15)

    Time frame: From 30 minutes through 336 hours (Day 15)

  4. AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active Comparator

    Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

    Time frame: From 30 minutes through 336 hours (Day 15)

  5. Difference in NRS-A Pain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to Placebo

    The NRS with activity (NRS-A) for pain intensity is an 11-item scale from 0 to 10 where participants rank the level of pain intensity after an activity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

    Time frame: Day 15

07

Results

Posted Oct 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneATX101Saline PlaceboBupivacaine Hydrochloride
Started929346
Enrolled899344
Completed879042
Not completed534

Outcome measures

PrimaryArea Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to Placebo

Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

Time frame:
from 30 minutes through 168 hours (Day 8)
Reported as:
Mean · score on a scale*hours
Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to Placebo
score on a scale*hoursATX101Saline Placebo
Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to Placebo980.61 ± 280.748985.19 ± 264.943
Statistical analysis
  • ATX101 vs Saline Placebo · ANOVA · p = 0.9011
SecondaryAUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo

Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

Time frame:
From 30 minutes through 336 hours (Day 15)
Reported as:
Mean · score on a scale*hours
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo
score on a scale*hoursATX101Saline Placebo
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo1811.50 ± 572.5861812.66 ± 547.247
Statistical analysis
  • ATX101 vs Saline Placebo · ANOVA · p = 0.9859
SecondaryAUC for the NRS-R of Pain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to Placebo

Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

Time frame:
From 30 minutes through 504 hours (Day 22)
Reported as:
Mean · score on a scale*hours
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to Placebo
score on a scale*hoursATX101Saline Placebo
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to Placebo2545.41 ± 875.9612536.75 ± 843.180
Statistical analysis
  • ATX101 vs Saline Placebo · ANOVA · p = 0.9445
SecondaryTotal Post-surgical Consumption of Opioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo

Total post-surgical consumption of rescue opioid medications in morphine milligrams equivalent (MME) dose from 30 minutes through 336 hours (Day 15)

Time frame:
From 30 minutes through 336 hours (Day 15)
Reported as:
Mean · Morphine Milligram Equivalents
Total Post-surgical Consumption of Opioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo
Morphine Milligram EquivalentsATX101Saline Placebo
Total Post-surgical Consumption of Opioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo233.416 ± 208.8313229.261 ± 187.0728
Statistical analysis
  • ATX101 vs Saline Placebo · ANOVA · p = 0.7328
SecondaryAUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active Comparator

Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

Time frame:
From 30 minutes through 336 hours (Day 15)
Reported as:
Mean · score on a scale*hours
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active Comparator
score on a scale*hoursATX101Bupivacaine Hydrochloride
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active Comparator1811.50 ± 572.5861852.07 ± 610.273
Statistical analysis
  • ATX101 vs Bupivacaine Hydrochloride · ANOVA · p = 0.7182
SecondaryDifference in NRS-A Pain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to Placebo

The NRS with activity (NRS-A) for pain intensity is an 11-item scale from 0 to 10 where participants rank the level of pain intensity after an activity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

Time frame:
Day 15
Reported as:
Mean · score on a scale
Difference in NRS-A Pain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to Placebo
score on a scaleATX101Saline Placebo
Difference in NRS-A Pain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to Placebo3.4 ± 2.103.6 ± 2.06
Statistical analysis
  • ATX101 vs Saline Placebo · ANOVA · p = 0.4180

Adverse events

Collected over Day 45. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATX1010/90 (0%)9/90 (10%)71/90 (78.9%)
Saline Placebo0/92 (0%)5/92 (5.4%)81/92 (88%)
Bupivacaine Hydrochloride0/44 (0%)1/44 (2.3%)35/44 (79.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventATX101Saline PlaceboBupivacaine Hydrochloride
Heart rate increasedInvestigations0/900/921/44
Respiratory rate increasedInvestigations0/900/921/44
Liver function test increasedInvestigations2/900/920/44
Muscle spasmsMusculoskeletal and connective tissue disorders1/900/920/44
Hepatitis AInfections and infestations1/900/920/44
Pilonidal diseaseInfections and infestations1/900/920/44
Deep vein thrombosisVascular disorders1/900/920/44
Orthostatic hypotensionVascular disorders1/900/920/44
ConstipationGastrointestinal disorders1/900/920/44
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/900/920/44
Most frequent other events
Showing 10 of 13
Most frequent other events
EventATX101Saline PlaceboBupivacaine Hydrochloride
NauseaGastrointestinal disorders27/9034/9213/44
VomitingGastrointestinal disorders10/9016/922/44
ConstipationGastrointestinal disorders15/9010/927/44
DizzinessNervous system disorders9/909/926/44
Blood pressure increasedInvestigations10/909/925/44
Blood pressure decreasedInvestigations2/907/924/44
HeadacheNervous system disorders8/908/923/44
Gamma-glutamyltransferase increasedInvestigations8/904/922/44
Liver function test increasedInvestigations8/904/920/44
HypoxiaRespiratory, thoracic and mediastinal disorders3/908/923/44

Baseline characteristics

Full Analysis Set (FAS)

Age, Categorical
Age, Categorical(Participants)ATX101Saline PlaceboBupivacaine HydrochlorideTotal
<=18 years0000
Between 18 and 65 years586032150
>=65 years31331276
Age, Continuous
Age, Continuous(years)ATX101Saline PlaceboBupivacaine HydrochlorideTotal
Mean61.2 ± 8.7461.0 ± 8.2361.8 ± 8.1261.3 ± 8.38
Sex: Female, Male
Sex: Female, Male(Participants)ATX101Saline PlaceboBupivacaine HydrochlorideTotal
Female465621123
Male433723103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATX101Saline PlaceboBupivacaine HydrochlorideTotal
American Indian or Alaska Native0011
Asian0000
Native Hawaiian or Other Pacific Islander1001
Black or African American16121038
White717833182
More than one race0000
Unknown or Not Reported1304
Region of Enrollment
Region of Enrollment(participants)ATX101Saline PlaceboBupivacaine HydrochlorideTotal
United States899344226
Body Mass Index(kg/m2)
Body Mass Index(kg/m2)(kg/m^2)ATX101Saline PlaceboBupivacaine HydrochlorideTotal
Mean33.465 ± 5.784133.900 ± 5.082434.346 ± 5.554733.816 ± 5.4452
08

Study locations

11 sites
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Phoenix Clinical Research
    Tamarac, Florida 33321, United States
  • Atlanta Centre for Medical Research
    Atlanta, Georgia 30331, United States
  • NextStage Clinical Research
    Wichita, Kansas 67214, United States
  • Chesapeake Research Group, LLC
    Pasadena, Maryland 21122, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • Memorial Hermann Village
    Houston, Texas 77043, United States
  • Endeavor Clinical Trials, LLC
    San Antonio, Texas 78240, United States
  • NextStage Clinical Research
    San Antonio, Texas 78258, United States
  • JBR Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Oct 2025, 8 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 8 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 29, 2025
StartActual
Feb 3, 2025
Primary completionActual
Oct 3, 2025
CompletionActual
Oct 3, 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedArea underUnder the curveCurve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of pain intensityPain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to PlaceboTime frame: from 30 minutes through 168 hours (Day 8) compared to placebo → from 30 minutes through 168 hours (Day 8)
Oct 19, 2026
Documents
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedAUC for the NRS-R of pain intensityPain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to PlaceboTime frame: 30 minutes through 336 hours (Day 15) compared to placebo → From 30 minutes through 336 hours (Day 15)
  • EditedAUC for the NRS-R of pain intensityPain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to PlaceboTime frame: from 30 minutes through 504 hours (Day 22) compared to placebo → From 30 minutes through 504 hours (Day 22)
  • EditedTotal postPost-surgical consumptionConsumption of opioid medicationsOpioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to PlaceboTime frame: from 30 minutes through 336 hours (Day 15) compared to placebo → From 30 minutes through 336 hours (Day 15)
  • EditedAUC for the NRS-R of pain intensityPain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active ComparatorTime frame: from 30 minutes through 336 hours (Day 15) compared to active comparator → From 30 minutes through 336 hours (Day 15)
  • EditedDifference in NRS-A pain intensity scores duringPain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to PlaceboTime frame: at Day 15 compared to placebo → Day 15
Oct 19, 2026
Title
Phase 2B Study Assessing Pain Relief After Replacement of the Knee
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedArea underUnder the curveCurve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of pain intensityPain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to PlaceboTime frame: from 30 minutes through 168 hours (Day 8) compared to placebo → from 30 minutes through 168 hours (Day 8)
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedAUC for the NRS-R of pain intensityPain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to PlaceboTime frame: 30 minutes through 336 hours (Day 15) compared to placebo → From 30 minutes through 336 hours (Day 15)
    • EditedAUC for the NRS-R of pain intensityPain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to PlaceboTime frame: from 30 minutes through 504 hours (Day 22) compared to placebo → From 30 minutes through 504 hours (Day 22)
    • EditedTotal postPost-surgical consumptionConsumption of opioid medicationsOpioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to PlaceboTime frame: from 30 minutes through 336 hours (Day 15) compared to placebo → From 30 minutes through 336 hours (Day 15)
    • EditedAUC for the NRS-R of pain intensityPain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active ComparatorTime frame: from 30 minutes through 336 hours (Day 15) compared to active comparator → From 30 minutes through 336 hours (Day 15)
    • EditedDifference in NRS-A pain intensity scores duringPain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to PlaceboTime frame: at Day 15 compared to placebo → Day 15
    Title Phase 2B Study Assessing Pain Relief After Replacement of the Knee
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06799845
Lead sponsor
Allay Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Feb 3, 2025
Primary completion
Oct 3, 2025
Completion
Oct 3, 2025
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

David Hewitt, MD
study director · Allay Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion